Skip to main content

A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.

Publication ,  Conference
Aghajanian, C; Filiaci, VL; Dizon, DS; Carlson, J; Powell, MA; Secord, AA; Tewari, KS; Bender, D; O'Malley, DM; Stuckey, A; Rotmensch, J ...
Published in: Journal of Clinical Oncology
May 20, 2015

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

5500 / 5500

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aghajanian, C., Filiaci, V. L., Dizon, D. S., Carlson, J., Powell, M. A., Secord, A. A., … Moore, K. N. (2015). A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. In Journal of Clinical Oncology (Vol. 33, pp. 5500–5500). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.5500
Aghajanian, Carol, Virginia L. Filiaci, Don S. Dizon, Jay Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu Sujata Tewari, et al. “A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.” In Journal of Clinical Oncology, 33:5500–5500. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5500.
Aghajanian C, Filiaci VL, Dizon DS, Carlson J, Powell MA, Secord AA, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 5500–5500.
Aghajanian, Carol, et al. “A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 5500–5500. Crossref, doi:10.1200/jco.2015.33.15_suppl.5500.
Aghajanian C, Filiaci VL, Dizon DS, Carlson J, Powell MA, Secord AA, Tewari KS, Bender D, O’Malley DM, Stuckey A, Rotmensch J, Levine DA, Lankes HA, Moore KN. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 5500–5500.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

5500 / 5500

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences